个人中心 - 老虎社区

G7

IP属地：未知

帖子 · 44帖子 · 44
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- G7G7
  ·2021-12-31
  $Razer(01337)$ New Year soon... Good news when?
  3,190 评论
  点赞
  分享
  举报
- G7G7
  ·2021-12-24
  $Razer(01337)$ News when? lol
  1,827 评论
  点赞
  分享
  举报
- G7G7
  ·2021-12-14
  lower more please
  Why Nvidia Stock Keeps Dropping<blockquote>英伟达股价为何持续下跌</blockquote>
  Nvidia has been a big gainer, but now other, smaller chip stocks look cheaper.
  Why Nvidia Stock Keeps Dropping<blockquote>英伟达股价为何持续下跌</blockquote>
  1,765 评论
  6
  分享
  举报
- G7G7
  ·2021-12-02
  for real?
  Razer will be privatized at a price of HK $2.82 per share<blockquote>雷蛇将以每股2.82港元的价格私有化</blockquote>
  A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10
  Razer will be privatized at a price of HK $2.82 per share<blockquote>雷蛇将以每股2.82港元的价格私有化</blockquote>
  1,956 评论
  6
  分享
  举报
- G7G7
  ·2021-11-24
  $Razer(01337)$come on baby
  1,521 评论
  4
  分享
  举报
- G7G7
  ·2021-11-22
  good
  Fujifilm to spend $5bn to become global contract drugmaker<blockquote>富士胶片将斥资50亿美元成为全球合同制药商</blockquote>
  Opportunity seen in outsourcing trend similar to chip industry Fujifilm plans to introduce a new pro
  Fujifilm to spend $5bn to become global contract drugmaker<blockquote>富士胶片将斥资50亿美元成为全球合同制药商</blockquote>
  3,052 2
  5
  分享
  举报
- G7G7
  ·2021-11-17
  $Nanofilm(MZH.SI)$lol what happened? pleasant surprise
  3,052 2
  4
  分享
  举报
- G7G7
  ·2021-11-17
  $Razer(01337)$ let's go
  1,750 评论
  4
  分享
  举报
- G7G7
  ·2021-11-16
  $Razer(01337)$ oooh more newshttps://www.reuters.com/article/razer-privatisation-idUSKBN2I10BK
  2,263 评论
  1
  分享
  举报
- G7G7
  ·2021-11-16
  $Razer(01337)$Nice
  3,151 评论
  2
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575098910724577","uuid":"3575098910724577","gmtCreate":1612004886936,"gmtModify":1629104032528,"name":"G7","pinyin":"g7","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":95,"tweetSize":44,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.13","exceedPercentage":"60.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692879309,"gmtCreate":1640924904201,"gmtModify":1640924913424,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>&nbsp;New Year soon... Good news when?","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>&nbsp;New Year soon... Good news when?","text":"$Razer(01337)$ New Year soon... Good news when?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692879309","isVote":1,"tweetType":1,"viewCount":3190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698111072,"gmtCreate":1640316263012,"gmtModify":1640316650415,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>&nbsp;News when? lol","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>&nbsp;News when? lol","text":"$Razer(01337)$ News when? lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698111072","isVote":1,"tweetType":1,"viewCount":1827,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607991523,"gmtCreate":1639469048269,"gmtModify":1639469048428,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"lower more please","listText":"lower more please","text":"lower more please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607991523","repostId":"1193701389","repostType":2,"repost":{"id":"1193701389","kind":"news","pubTimestamp":1639460770,"share":"https://www.laohu8.com/m/news/1193701389?lang=zh_CN&edition=full","pubTime":"2021-12-14 13:46","market":"us","language":"en","title":"Why Nvidia Stock Keeps Dropping<blockquote>英伟达股价为何持续下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1193701389","media":"Motley Fool","summary":"Nvidia has been a big gainer, but now other, smaller chip stocks look cheaper.","content":"<p><b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;semiconductor&nbsp;company&nbsp;<b>Nvidia</b>&nbsp;dropped again on Monday -- down 6.8% as of closed -- its fourth straight down day in a row. There doesn't appear to be any particular news behind today's decline, at least not specific to Nvidia.</p><p><blockquote>半导体公司股票<b>英伟达</b>周一再次下跌——截至收盘下跌6.8%——连续第四天下跌。今天的下跌背后似乎没有任何特别的消息，至少不是针对英伟达的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fe9777cd8866f53c260abe399593d3d0\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> From a big picture perspective, the news isn't great. CNBC reported this morning there's a risk that the ongoing chip shortage could depress Christmas shopping this year.</p><p><blockquote>从大局来看，这个消息并不好。CNBC今天早上报道称，持续的芯片短缺可能会抑制今年的圣诞购物。</blockquote></p><p> Although high demand for high-end Nvidia graphics chips is generally good news for the company and its pricing power, the network notes that \"semiconductors are beneath the hood of an increasing number of products,\" but \"things made with chips don't just use one chip.\" Thus, even a PC manufacturer lucky enough to get hold of all the Nvidia chips it needs might not be able to sell its PC if it can't also get all the power control, memory, and other chips it also needs to build the product. Or the manufacturer might not buy the Nvidia chips in the first place if it knows it won't be able to obtain the other chips.</p><p><blockquote>尽管对高端英伟达图形芯片的高需求通常对该公司及其定价能力来说是个好消息，但该网络指出，“半导体是越来越多产品的幕后黑手”，但“用芯片制造的东西并不只是使用一个芯片。”因此，即使是有幸获得其所需的所有Nvidia芯片的PC制造商，如果无法获得构建产品所需的所有电源控制、内存和其他芯片，也可能无法销售其PC。或者，如果制造商知道无法获得其他芯片，它可能一开始就不会购买Nvidia芯片。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> That's one risk Nvidia investors face. A bigger risk, though, may be its high-flying stock price.</p><p><blockquote>这是英伟达投资者面临的风险之一。不过，更大的风险可能是其飞涨的股价。</blockquote></p><p> This morning, analysts at&nbsp;<b>JPMorgan</b>, at&nbsp;<b>UBS</b>, at&nbsp;<b>Barclays</b>,<b>Citigroup</b>, R.W. Baird, and&nbsp;<b>Evercore</b>&nbsp;ISI cited a range of semiconductor chipmakers that they like and believe are undervalued, and Nvidia wasn't one of them. Morgan recommended&nbsp;<b>Qualcomm</b>&nbsp;for its earnings upside, Evercore picked&nbsp;<b>Micron</b>&nbsp;as a stock that is \"structurally undervalued,\" and Barclays, Baird, and Citi raised their price targets on&nbsp;<b>Broadcom</b>&nbsp;based on demand for its products,TheFly.com&nbsp;reported today.</p><p><blockquote>今天上午，分析师<b>摩根大通</b>，和<b>瑞银</b>，和<b>巴克莱银行</b>,<b>花旗集团</b>，R.W.贝尔德，和<b>Evercore</b>ISI列举了一系列他们喜欢并认为被低估的半导体芯片制造商，英伟达不在其中。摩根推荐<b>Qualcomm</b>由于其盈利上升，Evercore选择了<b>微米</b>作为一只“结构性被低估”的股票，巴克莱、贝尔德和花旗上调了目标价<b>Broadcom</b>根据对其产品的需求，TheFly.com今天报道。</blockquote></p><p> Nvidia shares sell for 93 times trailing earnings. Micron is valued at less than 17 times earnings; Qualcomm is at 23 times, and Broadcom is at 47. It's pretty clear why Wall Street might consider these stocks relatively better deals than Nvidia.</p><p><blockquote>Nvidia股票的售价是往绩市盈率的93倍。美光科技的市盈率不到17倍；高通为23倍，博通为47倍。很明显，为什么华尔街可能认为这些股票比英伟达相对更划算。</blockquote></p><p> And it's just as clear why some investors might have decided that now is a good time to&nbsp;cash out some Nvidia stock winnings, and reinvest them in relatively&nbsp;cheaper stocks.</p><p><blockquote>同样清楚的是，为什么一些投资者可能认为现在是兑现一些英伟达股票奖金并将其再投资于相对便宜的股票的好时机。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Nvidia Stock Keeps Dropping<blockquote>英伟达股价为何持续下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Nvidia Stock Keeps Dropping<blockquote>英伟达股价为何持续下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-14 13:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;semiconductor&nbsp;company&nbsp;<b>Nvidia</b>&nbsp;dropped again on Monday -- down 6.8% as of closed -- its fourth straight down day in a row. There doesn't appear to be any particular news behind today's decline, at least not specific to Nvidia.</p><p><blockquote>半导体公司股票<b>英伟达</b>周一再次下跌——截至收盘下跌6.8%——连续第四天下跌。今天的下跌背后似乎没有任何特别的消息，至少不是针对英伟达的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fe9777cd8866f53c260abe399593d3d0\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> From a big picture perspective, the news isn't great. CNBC reported this morning there's a risk that the ongoing chip shortage could depress Christmas shopping this year.</p><p><blockquote>从大局来看，这个消息并不好。CNBC今天早上报道称，持续的芯片短缺可能会抑制今年的圣诞购物。</blockquote></p><p> Although high demand for high-end Nvidia graphics chips is generally good news for the company and its pricing power, the network notes that \"semiconductors are beneath the hood of an increasing number of products,\" but \"things made with chips don't just use one chip.\" Thus, even a PC manufacturer lucky enough to get hold of all the Nvidia chips it needs might not be able to sell its PC if it can't also get all the power control, memory, and other chips it also needs to build the product. Or the manufacturer might not buy the Nvidia chips in the first place if it knows it won't be able to obtain the other chips.</p><p><blockquote>尽管对高端英伟达图形芯片的高需求通常对该公司及其定价能力来说是个好消息，但该网络指出，“半导体是越来越多产品的幕后黑手”，但“用芯片制造的东西并不只是使用一个芯片。”因此，即使是有幸获得其所需的所有Nvidia芯片的PC制造商，如果无法获得构建产品所需的所有电源控制、内存和其他芯片，也可能无法销售其PC。或者，如果制造商知道无法获得其他芯片，它可能一开始就不会购买Nvidia芯片。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> That's one risk Nvidia investors face. A bigger risk, though, may be its high-flying stock price.</p><p><blockquote>这是英伟达投资者面临的风险之一。不过，更大的风险可能是其飞涨的股价。</blockquote></p><p> This morning, analysts at&nbsp;<b>JPMorgan</b>, at&nbsp;<b>UBS</b>, at&nbsp;<b>Barclays</b>,<b>Citigroup</b>, R.W. Baird, and&nbsp;<b>Evercore</b>&nbsp;ISI cited a range of semiconductor chipmakers that they like and believe are undervalued, and Nvidia wasn't one of them. Morgan recommended&nbsp;<b>Qualcomm</b>&nbsp;for its earnings upside, Evercore picked&nbsp;<b>Micron</b>&nbsp;as a stock that is \"structurally undervalued,\" and Barclays, Baird, and Citi raised their price targets on&nbsp;<b>Broadcom</b>&nbsp;based on demand for its products,TheFly.com&nbsp;reported today.</p><p><blockquote>今天上午，分析师<b>摩根大通</b>，和<b>瑞银</b>，和<b>巴克莱银行</b>,<b>花旗集团</b>，R.W.贝尔德，和<b>Evercore</b>ISI列举了一系列他们喜欢并认为被低估的半导体芯片制造商，英伟达不在其中。摩根推荐<b>Qualcomm</b>由于其盈利上升，Evercore选择了<b>微米</b>作为一只“结构性被低估”的股票，巴克莱、贝尔德和花旗上调了目标价<b>Broadcom</b>根据对其产品的需求，TheFly.com今天报道。</blockquote></p><p> Nvidia shares sell for 93 times trailing earnings. Micron is valued at less than 17 times earnings; Qualcomm is at 23 times, and Broadcom is at 47. It's pretty clear why Wall Street might consider these stocks relatively better deals than Nvidia.</p><p><blockquote>Nvidia股票的售价是往绩市盈率的93倍。美光科技的市盈率不到17倍；高通为23倍，博通为47倍。很明显，为什么华尔街可能认为这些股票比英伟达相对更划算。</blockquote></p><p> And it's just as clear why some investors might have decided that now is a good time to&nbsp;cash out some Nvidia stock winnings, and reinvest them in relatively&nbsp;cheaper stocks.</p><p><blockquote>同样清楚的是，为什么一些投资者可能认为现在是兑现一些英伟达股票奖金并将其再投资于相对便宜的股票的好时机。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/13/why-nvidia-stock-keeps-dropping/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/12/13/why-nvidia-stock-keeps-dropping/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193701389","content_text":"What happened\nShares of semiconductor company Nvidia dropped again on Monday -- down 6.8% as of closed -- its fourth straight down day in a row. There doesn't appear to be any particular news behind today's decline, at least not specific to Nvidia.\nImage source: Getty Images.\nSo what\nFrom a big picture perspective, the news isn't great. CNBC reported this morning there's a risk that the ongoing chip shortage could depress Christmas shopping this year.\nAlthough high demand for high-end Nvidia graphics chips is generally good news for the company and its pricing power, the network notes that \"semiconductors are beneath the hood of an increasing number of products,\" but \"things made with chips don't just use one chip.\" Thus, even a PC manufacturer lucky enough to get hold of all the Nvidia chips it needs might not be able to sell its PC if it can't also get all the power control, memory, and other chips it also needs to build the product. Or the manufacturer might not buy the Nvidia chips in the first place if it knows it won't be able to obtain the other chips.\nNow what\nThat's one risk Nvidia investors face. A bigger risk, though, may be its high-flying stock price.\nThis morning, analysts at JPMorgan, at UBS, at Barclays,Citigroup, R.W. Baird, and Evercore ISI cited a range of semiconductor chipmakers that they like and believe are undervalued, and Nvidia wasn't one of them. Morgan recommended Qualcomm for its earnings upside, Evercore picked Micron as a stock that is \"structurally undervalued,\" and Barclays, Baird, and Citi raised their price targets on Broadcom based on demand for its products,TheFly.com reported today.\nNvidia shares sell for 93 times trailing earnings. Micron is valued at less than 17 times earnings; Qualcomm is at 23 times, and Broadcom is at 47. It's pretty clear why Wall Street might consider these stocks relatively better deals than Nvidia.\nAnd it's just as clear why some investors might have decided that now is a good time to cash out some Nvidia stock winnings, and reinvest them in relatively cheaper stocks.","news_type":1,"symbols_score_info":{"NVDA":0.9}},"isVote":1,"tweetType":1,"viewCount":1765,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603657271,"gmtCreate":1638408014836,"gmtModify":1638408015063,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"for real?&nbsp;","listText":"for real?&nbsp;","text":"for real?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603657271","repostId":"1197247033","repostType":2,"repost":{"id":"1197247033","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638406745,"share":"https://www.laohu8.com/m/news/1197247033?lang=zh_CN&edition=full","pubTime":"2021-12-02 08:59","market":"hk","language":"en","title":"Razer will be privatized at a price of HK $2.82 per share<blockquote>雷蛇将以每股2.82港元的价格私有化</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1197247033","media":"Tiger Newspress","summary":"A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10","content":"<p>A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10.79 billion Hong Kong dollars (US$1.38 billion) to take the Hong Kong-listed company private.</p><p><blockquote>由游戏设备制造商Razer Inc.创始人领导的财团已提出高达107.9亿港元（13.8亿美元）的报价，将这家在香港上市的公司私有化。</blockquote></p><p> Private-equity firm CVC Capital Partners is part of the consortium, Razer said Thursday in a filing to the Hong Kong bourse.</p><p><blockquote>雷蛇周四在提交给香港交易所的一份文件中表示，私募股权公司CVC Capital Partners是该财团的一部分。</blockquote></p><p> The consortium is offering HK$2.82 a share to buy all shares it doesn't currently hold, representing a 5.6% premium to the stock's last closing price. The offer is final, Razer said.</p><p><blockquote>该财团出价每股2.82港元购买其目前未持有的所有股份，较该股最后收盘价溢价5.6%。雷蛇表示，报价是最终的。</blockquote></p><p> Razer, which sells gear for gamers such as keyboards and headphones and has bases in California and Singapore, was founded in 2005 and went public in 2017. Shares are up 12% this year, but remain well below their initial public offering price.</p><p><blockquote>Razer成立于2005年，2017年上市，为游戏玩家销售键盘和耳机等设备，在加州和新加坡设有基地。今年股价上涨了12%，但仍远低于首次公开募股价格。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Razer will be privatized at a price of HK $2.82 per share<blockquote>雷蛇将以每股2.82港元的价格私有化</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRazer will be privatized at a price of HK $2.82 per share<blockquote>雷蛇将以每股2.82港元的价格私有化</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-02 08:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10.79 billion Hong Kong dollars (US$1.38 billion) to take the Hong Kong-listed company private.</p><p><blockquote>由游戏设备制造商Razer Inc.创始人领导的财团已提出高达107.9亿港元（13.8亿美元）的报价，将这家在香港上市的公司私有化。</blockquote></p><p> Private-equity firm CVC Capital Partners is part of the consortium, Razer said Thursday in a filing to the Hong Kong bourse.</p><p><blockquote>雷蛇周四在提交给香港交易所的一份文件中表示，私募股权公司CVC Capital Partners是该财团的一部分。</blockquote></p><p> The consortium is offering HK$2.82 a share to buy all shares it doesn't currently hold, representing a 5.6% premium to the stock's last closing price. The offer is final, Razer said.</p><p><blockquote>该财团出价每股2.82港元购买其目前未持有的所有股份，较该股最后收盘价溢价5.6%。雷蛇表示，报价是最终的。</blockquote></p><p> Razer, which sells gear for gamers such as keyboards and headphones and has bases in California and Singapore, was founded in 2005 and went public in 2017. Shares are up 12% this year, but remain well below their initial public offering price.</p><p><blockquote>Razer成立于2005年，2017年上市，为游戏玩家销售键盘和耳机等设备，在加州和新加坡设有基地。今年股价上涨了12%，但仍远低于首次公开募股价格。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01337":"雷蛇"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197247033","content_text":"A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10.79 billion Hong Kong dollars (US$1.38 billion) to take the Hong Kong-listed company private.\nPrivate-equity firm CVC Capital Partners is part of the consortium, Razer said Thursday in a filing to the Hong Kong bourse.\nThe consortium is offering HK$2.82 a share to buy all shares it doesn't currently hold, representing a 5.6% premium to the stock's last closing price. The offer is final, Razer said.\nRazer, which sells gear for gamers such as keyboards and headphones and has bases in California and Singapore, was founded in 2005 and went public in 2017. Shares are up 12% this year, but remain well below their initial public offering price.","news_type":1,"symbols_score_info":{"01337":0.9}},"isVote":1,"tweetType":1,"viewCount":1956,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874383653,"gmtCreate":1637730690136,"gmtModify":1637730690211,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>come on baby","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>come on baby","text":"$Razer(01337)$come on baby","images":[{"img":"https://static.tigerbbs.com/ad7a73051ad66984ade34ca81e8216ac","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874383653","isVote":1,"tweetType":1,"viewCount":1521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":872551136,"gmtCreate":1637550625535,"gmtModify":1637550650552,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/872551136","repostId":"1108872503","repostType":4,"repost":{"id":"1108872503","kind":"news","pubTimestamp":1637550331,"share":"https://www.laohu8.com/m/news/1108872503?lang=zh_CN&edition=full","pubTime":"2021-11-22 11:05","market":"us","language":"en","title":"Fujifilm to spend $5bn to become global contract drugmaker<blockquote>富士胶片将斥资50亿美元成为全球合同制药商</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108872503","media":"Nikkei Asia","summary":"Opportunity seen in outsourcing trend similar to chip industry\nFujifilm plans to introduce a new pro","content":"<p>Opportunity seen in outsourcing trend similar to chip industry</p><p><blockquote>类似芯片行业的外包趋势中看到的机会</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cffcbada03c1878d7dd688d377607e1\" tg-width=\"1400\" tg-height=\"787\" width=\"100%\" height=\"auto\"><span>Fujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)</span></p><p><blockquote><p class=\"t-img-caption\"><span>富士胶片计划在其英国工厂引入一种新的生产系统，可以更高效地生产高纯度抗体。（富士胶片供图）</span></p></blockquote></p><p> TOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.</p><p><blockquote>东京——富士胶片控股公司将其未来押注于成为其他制药公司的药物开发和制造服务提供商。</blockquote></p><p> The Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.</p><p><blockquote>这家日本公司正斥资6000亿日元（52.5亿美元）在一个预计未来几年将快速增长的市场中站稳脚跟。它在6月底决定增加900亿日元的投资，押注它可以成为制药业对专门制造他人设计的计算机芯片的台积电公司的回答。</blockquote></p><p> As in the chip industry, there is a growing trend among big drugmakers to farm out some or all of their development and manufacturing to specialists. One factor driving the trend is the growing diversity of treatments and drugmaking technologies.</p><p><blockquote>与芯片行业一样，大型制药商越来越倾向于将部分或全部开发和制造外包给专家。推动这一趋势的一个因素是治疗和制药技术的日益多样化。</blockquote></p><p> As new treatments such as antibody drugs, cell therapies and gene therapies have become widely available, pharmaceutical companies face much tougher challenges developing and marketing drugs.</p><p><blockquote>随着抗体药物、细胞疗法和基因疗法等新疗法的广泛应用，制药公司在开发和营销药物方面面临着更加严峻的挑战。</blockquote></p><p> Another factor is the huge investment needed to develop and manufacture biopharmaceuticals -- drugs derived from biological processes, such as blood products. This has opened the door for contract development and manufacturing organizations (CDMOs) of the sort Fujifilm hopes to become.</p><p><blockquote>另一个因素是开发和制造生物制药所需的巨额投资——来自生物过程的药物，如血液制品。这为富士胶片希望成为的合同开发和制造组织(CDMO)打开了大门。</blockquote></p><p> Developing a new drug and bringing it to the market typically takes around 10 years and carries with it a huge risk of failure. The economics of the business argue for outsourcing: It makes sense for pharmaceutical companies to focus on lab operations drug discovery, and leaving steps such as cell line development, clinical trials and commercial manufacturing to service providers like CDMOs. \"We want to focus our management resources on drug discovery and marketing,\" says an executive at a major Japanese drugmaker.</p><p><blockquote>开发一种新药并将其推向市场通常需要大约10年的时间，并且伴随着巨大的失败风险。商业经济学支持外包：制药公司专注于实验室运营药物发现，将细胞系开发、临床试验和商业制造等步骤留给CDMO等服务提供商是有意义的。“我们希望将管理资源集中在药物发现和营销上，”日本一家大型制药商的高管表示。</blockquote></p><p> Takahiro Mori, a senior analyst at Mizuho Securities, predicts steady growth for outsourcing in the biopharmaceutical industry. \"Major pharmaceutical companies are putting less priority on investment in complex and sophisticated production technology for such drugs,\" he points out.</p><p><blockquote>瑞穗证券高级分析师Takahiro Mori预测生物制药行业的外包将稳步增长。“大型制药公司不再优先考虑对此类药物复杂精密生产技术的投资，”他指出。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d4e0ef42e741341d1e8a618f8564c23\" tg-width=\"770\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Fujifilm believes it can be a major player in contract development and manufacturing of drugs by capitalizing on its competitive production technology. (File photo by AP)</span></p><p><blockquote><p class=\"t-img-caption\"><span>富士胶片相信，通过利用其有竞争力的生产技术，它可以成为药物合同开发和制造的主要参与者。（美联社资料照片）</span></p></blockquote></p><p> In fact, more big drugmakers are selling off their manufacturing operations these days. Swiss pharmaceutical giant Novartis sold its U.S. production facility for gene therapies to AGC in August. AstraZeneca of Britain sold its U.S. plant to AGC in June 2020.</p><p><blockquote>事实上，如今越来越多的大型制药商正在出售其制造业务。瑞士制药巨头诺华于8月将其在美国的基因疗法生产设施出售给AGC。英国阿斯利康于2020年6月将其美国工厂出售给AGC。</blockquote></p><p> Research and Markets has forecast the CDMO market will grow by 50% to $241 billion by 2024, compared with 2020. The market is currently dominated by Lonza Group, a Swiss company, Boehringer Ingelheim of Germany and Samsung Biologics of South Korea. Together, they control around 70% of the global market in terms of production capacity.</p><p><blockquote>Research and Markets预测，到2024年，CDMO市场将比2020年增长50%，达到2410亿美元。该市场目前由瑞士龙沙集团、德国勃林格殷格翰和韩国三星生物制品公司主导。就产能而言，它们合计控制着全球市场约70%的份额。</blockquote></p><p> In particular, Samsung Biologics is using its financial muscle to expand, spending around $1.4 billion on a new plant that will raise its capacity by 70% next year. It has further plans for growth</p><p><blockquote>特别是，三星生物制品公司正在利用其财务实力进行扩张，斥资约14亿美元建设新工厂，明年产能将提高70%。它有进一步的增长计划</blockquote></p><p> Fujifilm is late to the race but hopes its competitive production technology will help it catch up. The Japanese company plans to introduce a new production system that can more efficiently make antibodies with high purity in its plant in the U.K. Fujifilm describes the system as a \"fully integrated continuous processing facility.\"</p><p><blockquote>富士胶片在这场竞赛中姗姗来迟，但希望其有竞争力的生产技术将帮助其迎头赶上。这家日本公司计划在其英国工厂引入一种新的生产系统，可以更有效地生产高纯度抗体。富士胶片将该系统描述为“完全集成的连续加工设施”。</blockquote></p><p> Fujifilm's continuous processing approach offers a cost-effective alternative to traditional batch cell culturing, allowing higher efficiency, along with better, more consistent product quality, the company says. Because it allows continuous production, the system does not require large tanks, reducing the required investment by 70% and overall production costs by around 30%, according to Fujifilm. The company says the amount of antibodies that can be harvested is three times higher with its continuous production method, compared with conventional batch production.</p><p><blockquote>该公司表示，富士胶片的连续处理方法为传统的批量细胞培养提供了一种经济高效的替代方案，可以实现更高的效率以及更好、更一致的产品质量。富士胶片表示，由于该系统允许连续生产，因此不需要大型储罐，因此所需投资减少了70%，总体生产成本降低了30%左右。该公司表示，与传统批量生产相比，其连续生产方法可收获的抗体量高出三倍。</blockquote></p><p></p><p> Continuous production, however, requires highly precise control of the entire cell culturing process, as well as sophisticated refining technology and equipment. It also demands an enormous amount of culture media -- 30 to 40 times more than is used in batch production. These technological and cost challenges have hindered widespread use of continuous production for biopharmaceuticals. Fujifilm has taken advantage of its design capabilities in film production and other businesses to develop new equipment for its continuous production system.</p><p><blockquote>然而，连续生产需要对整个细胞培养过程进行高度精确的控制，以及精密的精制技术和设备。它还需要大量的培养基——比批量生产中使用的培养基多30到40倍。这些技术和成本挑战阻碍了生物制药连续生产的广泛使用。富士胶片利用其在胶片生产和其他业务中的设计能力，为其连续生产系统开发了新设备。</blockquote></p><p> Takatoshi Ishikawa, a senior executive vice president in charge of the company's Bio CDMO division, calls Fujifilm's new production system \"a game-changer\" that will put it in a strong position to become the market leader. The company is already in talks with more than one major pharmaceutical company over the new technology.</p><p><blockquote>负责该公司生物CDMO部门的高级执行副总裁Takatoshi Ishikawa表示，评级富士胶片的新生产系统“改变了游戏规则”，将使其处于成为市场领导者的有利地位。该公司已经在与不止一家大型制药公司就这项新技术进行谈判。</blockquote></p><p> Fujifilm aims to raise the sales in its CDMO business to 200 billion yen by the year through March 2025, double the figure for the year that ended in March 2021, and achieve annual sales growth of 20% in subsequent years.</p><p><blockquote>富士胶片的目标是到2025年3月将CDMO业务的销售额提高到2000亿日元，比截至2021年3月的一年翻一番，并在随后几年实现20%的年销售额增长。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fujifilm to spend $5bn to become global contract drugmaker<blockquote>富士胶片将斥资50亿美元成为全球合同制药商</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFujifilm to spend $5bn to become global contract drugmaker<blockquote>富士胶片将斥资50亿美元成为全球合同制药商</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Nikkei Asia</strong><span class=\"h-time small\">2021-11-22 11:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Opportunity seen in outsourcing trend similar to chip industry</p><p><blockquote>类似芯片行业的外包趋势中看到的机会</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cffcbada03c1878d7dd688d377607e1\" tg-width=\"1400\" tg-height=\"787\" width=\"100%\" height=\"auto\"><span>Fujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)</span></p><p><blockquote><p class=\"t-img-caption\"><span>富士胶片计划在其英国工厂引入一种新的生产系统，可以更高效地生产高纯度抗体。（富士胶片供图）</span></p></blockquote></p><p> TOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.</p><p><blockquote>东京——富士胶片控股公司将其未来押注于成为其他制药公司的药物开发和制造服务提供商。</blockquote></p><p> The Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.</p><p><blockquote>这家日本公司正斥资6000亿日元（52.5亿美元）在一个预计未来几年将快速增长的市场中站稳脚跟。它在6月底决定增加900亿日元的投资，押注它可以成为制药业对专门制造他人设计的计算机芯片的台积电公司的回答。</blockquote></p><p> As in the chip industry, there is a growing trend among big drugmakers to farm out some or all of their development and manufacturing to specialists. One factor driving the trend is the growing diversity of treatments and drugmaking technologies.</p><p><blockquote>与芯片行业一样，大型制药商越来越倾向于将部分或全部开发和制造外包给专家。推动这一趋势的一个因素是治疗和制药技术的日益多样化。</blockquote></p><p> As new treatments such as antibody drugs, cell therapies and gene therapies have become widely available, pharmaceutical companies face much tougher challenges developing and marketing drugs.</p><p><blockquote>随着抗体药物、细胞疗法和基因疗法等新疗法的广泛应用，制药公司在开发和营销药物方面面临着更加严峻的挑战。</blockquote></p><p> Another factor is the huge investment needed to develop and manufacture biopharmaceuticals -- drugs derived from biological processes, such as blood products. This has opened the door for contract development and manufacturing organizations (CDMOs) of the sort Fujifilm hopes to become.</p><p><blockquote>另一个因素是开发和制造生物制药所需的巨额投资——来自生物过程的药物，如血液制品。这为富士胶片希望成为的合同开发和制造组织(CDMO)打开了大门。</blockquote></p><p> Developing a new drug and bringing it to the market typically takes around 10 years and carries with it a huge risk of failure. The economics of the business argue for outsourcing: It makes sense for pharmaceutical companies to focus on lab operations drug discovery, and leaving steps such as cell line development, clinical trials and commercial manufacturing to service providers like CDMOs. \"We want to focus our management resources on drug discovery and marketing,\" says an executive at a major Japanese drugmaker.</p><p><blockquote>开发一种新药并将其推向市场通常需要大约10年的时间，并且伴随着巨大的失败风险。商业经济学支持外包：制药公司专注于实验室运营药物发现，将细胞系开发、临床试验和商业制造等步骤留给CDMO等服务提供商是有意义的。“我们希望将管理资源集中在药物发现和营销上，”日本一家大型制药商的高管表示。</blockquote></p><p> Takahiro Mori, a senior analyst at Mizuho Securities, predicts steady growth for outsourcing in the biopharmaceutical industry. \"Major pharmaceutical companies are putting less priority on investment in complex and sophisticated production technology for such drugs,\" he points out.</p><p><blockquote>瑞穗证券高级分析师Takahiro Mori预测生物制药行业的外包将稳步增长。“大型制药公司不再优先考虑对此类药物复杂精密生产技术的投资，”他指出。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d4e0ef42e741341d1e8a618f8564c23\" tg-width=\"770\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Fujifilm believes it can be a major player in contract development and manufacturing of drugs by capitalizing on its competitive production technology. (File photo by AP)</span></p><p><blockquote><p class=\"t-img-caption\"><span>富士胶片相信，通过利用其有竞争力的生产技术，它可以成为药物合同开发和制造的主要参与者。（美联社资料照片）</span></p></blockquote></p><p> In fact, more big drugmakers are selling off their manufacturing operations these days. Swiss pharmaceutical giant Novartis sold its U.S. production facility for gene therapies to AGC in August. AstraZeneca of Britain sold its U.S. plant to AGC in June 2020.</p><p><blockquote>事实上，如今越来越多的大型制药商正在出售其制造业务。瑞士制药巨头诺华于8月将其在美国的基因疗法生产设施出售给AGC。英国阿斯利康于2020年6月将其美国工厂出售给AGC。</blockquote></p><p> Research and Markets has forecast the CDMO market will grow by 50% to $241 billion by 2024, compared with 2020. The market is currently dominated by Lonza Group, a Swiss company, Boehringer Ingelheim of Germany and Samsung Biologics of South Korea. Together, they control around 70% of the global market in terms of production capacity.</p><p><blockquote>Research and Markets预测，到2024年，CDMO市场将比2020年增长50%，达到2410亿美元。该市场目前由瑞士龙沙集团、德国勃林格殷格翰和韩国三星生物制品公司主导。就产能而言，它们合计控制着全球市场约70%的份额。</blockquote></p><p> In particular, Samsung Biologics is using its financial muscle to expand, spending around $1.4 billion on a new plant that will raise its capacity by 70% next year. It has further plans for growth</p><p><blockquote>特别是，三星生物制品公司正在利用其财务实力进行扩张，斥资约14亿美元建设新工厂，明年产能将提高70%。它有进一步的增长计划</blockquote></p><p> Fujifilm is late to the race but hopes its competitive production technology will help it catch up. The Japanese company plans to introduce a new production system that can more efficiently make antibodies with high purity in its plant in the U.K. Fujifilm describes the system as a \"fully integrated continuous processing facility.\"</p><p><blockquote>富士胶片在这场竞赛中姗姗来迟，但希望其有竞争力的生产技术将帮助其迎头赶上。这家日本公司计划在其英国工厂引入一种新的生产系统，可以更有效地生产高纯度抗体。富士胶片将该系统描述为“完全集成的连续加工设施”。</blockquote></p><p> Fujifilm's continuous processing approach offers a cost-effective alternative to traditional batch cell culturing, allowing higher efficiency, along with better, more consistent product quality, the company says. Because it allows continuous production, the system does not require large tanks, reducing the required investment by 70% and overall production costs by around 30%, according to Fujifilm. The company says the amount of antibodies that can be harvested is three times higher with its continuous production method, compared with conventional batch production.</p><p><blockquote>该公司表示，富士胶片的连续处理方法为传统的批量细胞培养提供了一种经济高效的替代方案，可以实现更高的效率以及更好、更一致的产品质量。富士胶片表示，由于该系统允许连续生产，因此不需要大型储罐，因此所需投资减少了70%，总体生产成本降低了30%左右。该公司表示，与传统批量生产相比，其连续生产方法可收获的抗体量高出三倍。</blockquote></p><p></p><p> Continuous production, however, requires highly precise control of the entire cell culturing process, as well as sophisticated refining technology and equipment. It also demands an enormous amount of culture media -- 30 to 40 times more than is used in batch production. These technological and cost challenges have hindered widespread use of continuous production for biopharmaceuticals. Fujifilm has taken advantage of its design capabilities in film production and other businesses to develop new equipment for its continuous production system.</p><p><blockquote>然而，连续生产需要对整个细胞培养过程进行高度精确的控制，以及精密的精制技术和设备。它还需要大量的培养基——比批量生产中使用的培养基多30到40倍。这些技术和成本挑战阻碍了生物制药连续生产的广泛使用。富士胶片利用其在胶片生产和其他业务中的设计能力，为其连续生产系统开发了新设备。</blockquote></p><p> Takatoshi Ishikawa, a senior executive vice president in charge of the company's Bio CDMO division, calls Fujifilm's new production system \"a game-changer\" that will put it in a strong position to become the market leader. The company is already in talks with more than one major pharmaceutical company over the new technology.</p><p><blockquote>负责该公司生物CDMO部门的高级执行副总裁Takatoshi Ishikawa表示，评级富士胶片的新生产系统“改变了游戏规则”，将使其处于成为市场领导者的有利地位。该公司已经在与不止一家大型制药公司就这项新技术进行谈判。</blockquote></p><p> Fujifilm aims to raise the sales in its CDMO business to 200 billion yen by the year through March 2025, double the figure for the year that ended in March 2021, and achieve annual sales growth of 20% in subsequent years.</p><p><blockquote>富士胶片的目标是到2025年3月将CDMO业务的销售额提高到2000亿日元，比截至2021年3月的一年翻一番，并在随后几年实现20%的年销售额增长。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://asia.nikkei.com/Business/Health-Care/Fujifilm-to-spend-5bn-to-become-global-contract-drugmaker\">Nikkei Asia</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FUJIF":"FUJIFILM Holdings Corp."},"source_url":"https://asia.nikkei.com/Business/Health-Care/Fujifilm-to-spend-5bn-to-become-global-contract-drugmaker","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108872503","content_text":"Opportunity seen in outsourcing trend similar to chip industry\nFujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)\nTOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.\nThe Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.\nAs in the chip industry, there is a growing trend among big drugmakers to farm out some or all of their development and manufacturing to specialists. One factor driving the trend is the growing diversity of treatments and drugmaking technologies.\nAs new treatments such as antibody drugs, cell therapies and gene therapies have become widely available, pharmaceutical companies face much tougher challenges developing and marketing drugs.\nAnother factor is the huge investment needed to develop and manufacture biopharmaceuticals -- drugs derived from biological processes, such as blood products. This has opened the door for contract development and manufacturing organizations (CDMOs) of the sort Fujifilm hopes to become.\nDeveloping a new drug and bringing it to the market typically takes around 10 years and carries with it a huge risk of failure. The economics of the business argue for outsourcing: It makes sense for pharmaceutical companies to focus on lab operations drug discovery, and leaving steps such as cell line development, clinical trials and commercial manufacturing to service providers like CDMOs. \"We want to focus our management resources on drug discovery and marketing,\" says an executive at a major Japanese drugmaker.\nTakahiro Mori, a senior analyst at Mizuho Securities, predicts steady growth for outsourcing in the biopharmaceutical industry. \"Major pharmaceutical companies are putting less priority on investment in complex and sophisticated production technology for such drugs,\" he points out.\nFujifilm believes it can be a major player in contract development and manufacturing of drugs by capitalizing on its competitive production technology. (File photo by AP)\nIn fact, more big drugmakers are selling off their manufacturing operations these days. Swiss pharmaceutical giant Novartis sold its U.S. production facility for gene therapies to AGC in August. AstraZeneca of Britain sold its U.S. plant to AGC in June 2020.\nResearch and Markets has forecast the CDMO market will grow by 50% to $241 billion by 2024, compared with 2020. The market is currently dominated by Lonza Group, a Swiss company, Boehringer Ingelheim of Germany and Samsung Biologics of South Korea. Together, they control around 70% of the global market in terms of production capacity.\nIn particular, Samsung Biologics is using its financial muscle to expand, spending around $1.4 billion on a new plant that will raise its capacity by 70% next year. It has further plans for growth\nFujifilm is late to the race but hopes its competitive production technology will help it catch up. The Japanese company plans to introduce a new production system that can more efficiently make antibodies with high purity in its plant in the U.K. Fujifilm describes the system as a \"fully integrated continuous processing facility.\"\nFujifilm's continuous processing approach offers a cost-effective alternative to traditional batch cell culturing, allowing higher efficiency, along with better, more consistent product quality, the company says. Because it allows continuous production, the system does not require large tanks, reducing the required investment by 70% and overall production costs by around 30%, according to Fujifilm. The company says the amount of antibodies that can be harvested is three times higher with its continuous production method, compared with conventional batch production.\nContinuous production, however, requires highly precise control of the entire cell culturing process, as well as sophisticated refining technology and equipment. It also demands an enormous amount of culture media -- 30 to 40 times more than is used in batch production. These technological and cost challenges have hindered widespread use of continuous production for biopharmaceuticals. Fujifilm has taken advantage of its design capabilities in film production and other businesses to develop new equipment for its continuous production system.\nTakatoshi Ishikawa, a senior executive vice president in charge of the company's Bio CDMO division, calls Fujifilm's new production system \"a game-changer\" that will put it in a strong position to become the market leader. The company is already in talks with more than one major pharmaceutical company over the new technology.\nFujifilm aims to raise the sales in its CDMO business to 200 billion yen by the year through March 2025, double the figure for the year that ended in March 2021, and achieve annual sales growth of 20% in subsequent years.","news_type":1,"symbols_score_info":{"FUJIF":0.9}},"isVote":1,"tweetType":1,"viewCount":3052,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878354205,"gmtCreate":1637154040638,"gmtModify":1637154040835,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MZH.SI\">$Nanofilm(MZH.SI)$</a>lol what happened? pleasant surprise","listText":"<a href=\"https://laohu8.com/S/MZH.SI\">$Nanofilm(MZH.SI)$</a>lol what happened? pleasant surprise","text":"$Nanofilm(MZH.SI)$lol what happened? pleasant surprise","images":[{"img":"https://static.tigerbbs.com/f3bb9ca3f3e783c9a2c0d58a68a524b2","width":"1080","height":"3164"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/878354205","isVote":1,"tweetType":1,"viewCount":3052,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":871728191,"gmtCreate":1637114399056,"gmtModify":1637114735467,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>&nbsp;let's go","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>&nbsp;let's go","text":"$Razer(01337)$ let's go","images":[{"img":"https://static.tigerbbs.com/a26aa0846bf8111b623c3546d2a067a4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871728191","isVote":1,"tweetType":1,"viewCount":1750,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":871126491,"gmtCreate":1637039077358,"gmtModify":1637039590331,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>&nbsp;oooh more newshttps://www.reuters.com/article/razer-privatisation-idUSKBN2I10BK&nbsp;","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>&nbsp;oooh more newshttps://www.reuters.com/article/razer-privatisation-idUSKBN2I10BK&nbsp;","text":"$Razer(01337)$ oooh more newshttps://www.reuters.com/article/razer-privatisation-idUSKBN2I10BK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871126491","isVote":1,"tweetType":1,"viewCount":2263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871112628,"gmtCreate":1637035943907,"gmtModify":1637035944003,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>Nice","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>Nice","text":"$Razer(01337)$Nice","images":[{"img":"https://static.tigerbbs.com/5a94448ca36d308564eb0f0db2bff460","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871112628","isVote":1,"tweetType":1,"viewCount":3151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}